Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) traded up 1.7% during mid-day trading on Thursday . The stock traded as high as $54.14 and last traded at $53.74. 366,596 shares traded hands during mid-day trading, an increase of 94% from the average session volume of 189,291 shares. The stock had previously closed at $52.83.
Gemini Therapeutics Stock Performance
The stock’s 50 day simple moving average is $55.59 and its 200 day simple moving average is $55.96. The firm has a market cap of $2.33 billion, a P/E ratio of -53.74 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- Using the MarketBeat Stock Split Calculator
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- What is MarketRank™? How to Use it
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Business Services Stocks Investing
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
